Latest Articles

Publication Date
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More - Targeted Oncology

The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More Targeted Oncology

Published: June 23, 2024, 7 a.m.
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer - Oncology News Central

FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer Oncology News Central

Published: June 17, 2024, 7 a.m.
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - PR Newswire

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting PR Newswire

Published: April 24, 2024, 7 a.m.
Education Session to Discuss the Implementation of New Drugs in Gynecologic Oncology - ASCO Daily News

Education Session to Discuss the Implementation of New Drugs in Gynecologic Oncology ASCO Daily News

Published: April 24, 2024, 7 a.m.
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - Investor Relations | Karyopharm Therapeutics

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting Investor Relations | Karyopharm Therapeutics

Published: April 24, 2024, 7 a.m.
Molecular Classification May Predict Survival Outcomes in Endometrial Cancer - Oncology Learning Network

Molecular Classification May Predict Survival Outcomes in Endometrial Cancer Oncology Learning Network

Published: April 1, 2024, 7 a.m.
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer - Oncology Learning Network

Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer Oncology Learning Network

Published: March 21, 2024, 7 a.m.
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer - Oncology News Central

Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer Oncology News Central

Published: March 20, 2024, 7 a.m.
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer - Oncology News Central

“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer Oncology News Central

Published: March 17, 2024, 7 a.m.
KEYNOTE-A18 Eligibility: Pembro/Chemoradiotherapy in Cervical Cancer - Targeted Oncology

KEYNOTE-A18 Eligibility: Pembro/Chemoradiotherapy in Cervical Cancer Targeted Oncology

Published: Jan. 5, 2024, 8 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!